Zacks Research Has Positive Forecast for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Stock analysts at Zacks Research increased their Q1 2026 earnings estimates for Iovance Biotherapeutics in a research note issued to investors on Tuesday, March 17th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of ($0.21) per share for the quarter, up from their prior forecast of ($0.22). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.69) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.20) EPS.

Several other equities analysts have also recently weighed in on IOVA. The Goldman Sachs Group restated a “sell” rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Barclays increased their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. UBS Group raised their price target on Iovance Biotherapeutics from $2.00 to $4.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. Chardan Capital lowered their price target on Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Finally, Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective on the stock in a research note on Tuesday, March 3rd. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Iovance Biotherapeutics currently has an average rating of “Hold” and a consensus price target of $8.88.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA opened at $3.69 on Thursday. The company’s 50-day moving average price is $3.19 and its two-hundred day moving average price is $2.62. Iovance Biotherapeutics has a one year low of $1.64 and a one year high of $5.63. The stock has a market capitalization of $1.52 billion, a PE ratio of -3.29 and a beta of 0.69.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The business had revenue of $86.77 million during the quarter, compared to the consensus estimate of $81.61 million.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several hedge funds have recently bought and sold shares of the company. State Street Corp increased its position in Iovance Biotherapeutics by 51.5% during the fourth quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after buying an additional 6,851,486 shares during the last quarter. Palo Alto Investors LP lifted its position in shares of Iovance Biotherapeutics by 122.1% in the third quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock valued at $16,531,000 after buying an additional 4,188,803 shares during the last quarter. HRT Financial LP lifted its position in shares of Iovance Biotherapeutics by 1,078.3% in the fourth quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company’s stock valued at $11,891,000 after buying an additional 3,986,314 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Iovance Biotherapeutics by 202.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after acquiring an additional 3,869,617 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Iovance Biotherapeutics by 13.1% during the 4th quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after acquiring an additional 3,148,096 shares during the period. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Zacks bumped multiple 2026 estimates (Q1–Q4 2026) and raised its FY2026 EPS forecast to ($0.69) from ($0.74), indicating a modest improvement in the near‑term earnings outlook. Zacks raises 2026 estimates for Iovance (3/17/2026)
• Neutral Sentiment: Zacks published a set of multi‑year estimates (including FY2028 at ($0.20) and detailed quarterly targets through 2027–2028). These projections provide more visibility but are forward looking and depend on clinical/regulatory progress and commercialization execution. Zacks issues FY2028 and multi‑quarter estimates for Iovance (3/17/2026)
• Negative Sentiment: Zacks trimmed several 2027 quarterly estimates (Q2 2027 to ($0.14) from ($0.13); Q3 2027 to ($0.10) from ($0.09); Q4 2027 to ($0.08) from ($0.07)) and lowered its FY2027 EPS call to ($0.47) from ($0.45). These downward revisions to 2027 guidance likely drove negative sentiment and contributed to the stock moving lower. Zacks cuts 2027 estimates for Iovance (3/17/2026)

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.